Share

INTERACT

Ranolazine to treat early cardiotoxicity induced by antitumor drugs

Project objectives

Prospective multicenter Phase IIB study, low risk, with competitive enrollment, to evaluate the efficacy and tolerability of ranolazine or standard cardiovascular drugs in the treatment of symptoms and/or echocardiographic or biohumoral evidence of early cardiotoxicity induced by standard chemotherapies for the treatment of non-lymphoma Hodgkin or adjuvant therapy of breast or colorectal cancer.

Start and end date
January 2011 - November 2015

Project Manager
Prof. Giorgio Minotti Head of Pharmaceutical Sciences UR, Università Campus Bio-Medico di Roma and Fondazione Policlinico Universitario Campus Bio-Medico, Rome - Principal Investigator

Coordinating institution of the project
UR Pharmaceutical Sciences, Departmental Faculty of Medicine and Surgery, Integrated Research Center, Campus Bio-Medico University, Rome

Other Institutions involved
  • IRCCS National Cancer Institute “Regina Elena”, Rome
  • IRCCS San Martino Polyclinic Hospital, Genoa
  • IRCCS National Cancer Institute, Naples
  • Oncology Center Giovanni XXIII, Bari
  • Gavazzeni Foundation, Bergamo
  • Tor Vergata University, Rome
  • La Sapienza University, Rome
  • University of Trieste, Trieste
  • Grassi Hospital, Ostia (Rome)
  • San Pietro Hospital, Rome

Funding source(s).
• Menarini International Operation Luxembourg, sa
2023© Università Campus Bio-Medico di Roma, Via Álvaro del Portillo, 21 - 00128 Rome, Tel. +39 06.22541.1, Fax +39 06.22541.456, VAT number: 048 020 51 005, Fiscal Code: 97087620585
QUICK LINKS
L'Università Campus Bio-Medico di Roma promotes integrated teaching and research structures, pursuing the good of the person as the main aim of its activities.
magnifiercrossmenuchevron-downchevron-leftchevron-right